ForCast Orthopedics announced the initial closing of a Series A equity financing round to support the development of its novel therapies for periprosthetic joint infection (PJI). The financing was led by OrthoInnovations LLC.
PJI is a rare but serious complication of joint replacement procedures that can threaten the function of the joint, the preservation of the limb and even the life of the patient. PJI is challenging to treat because the infecting bacteria adhere to the prothesis and form a protective biofilm that can be resistant to standard systemic antibiotics. ForCast intends to address these challenges by developing a portfolio of targeted antibiotic therapies delivered directly into the infected joint using ForCast’s proprietary technology.
“Peter Noymer, PhD, Executive Chairman and CEO of ForCast, said, “Building upon our earlier successes in obtaining Orphan Drug and Qualified Infectious Disease Product designations from the FDA, we look forward to continuing that momentum as we work to bring our novel therapies to patients.”
ForCast Orthopedics announced the initial closing of a Series A equity financing round to support the development of its novel therapies for periprosthetic joint infection (PJI). The financing was led by OrthoInnovations LLC.
PJI is a rare but serious complication of joint replacement procedures that can threaten the function of the joint, the...
ForCast Orthopedics announced the initial closing of a Series A equity financing round to support the development of its novel therapies for periprosthetic joint infection (PJI). The financing was led by OrthoInnovations LLC.
PJI is a rare but serious complication of joint replacement procedures that can threaten the function of the joint, the preservation of the limb and even the life of the patient. PJI is challenging to treat because the infecting bacteria adhere to the prothesis and form a protective biofilm that can be resistant to standard systemic antibiotics. ForCast intends to address these challenges by developing a portfolio of targeted antibiotic therapies delivered directly into the infected joint using ForCast’s proprietary technology.
“Peter Noymer, PhD, Executive Chairman and CEO of ForCast, said, “Building upon our earlier successes in obtaining Orphan Drug and Qualified Infectious Disease Product designations from the FDA, we look forward to continuing that momentum as we work to bring our novel therapies to patients.”
Copy to clipboard 
